CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SciClone Pharmaceuticals (Holdings) Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SciClone Pharmaceuticals (Holdings) Ltd
22/F
Central Plaza, 381 Middle Huaihai Road
SHANGHAI, SHA  China
On 7/5/2024, the Company was acquired by GL Capital Group in a take-private transaction
This company is no longer actively traded on any major stock exchange.
Business Summary
SciClone Pharmaceuticals (Holdings) Ltd is a company principally engaged in the provision of treatment plans for tumors and severe infectious diseases. The Company and its subsidiaries are principally engaged in developing and commercializing a portfolio of marketed products as well as pipelines with potential in their focused therapeutic areas including oncology and severe infection. The Company’s main products comprise Zadaxin, Zometa, Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro. The Company’s pipeline products include ORSERDU, Vaborem, Vibativ, RRx-001 and Omburtamab. The Company’s products are mainly used in fields such as tumors, urinary tract infections, and skin and soft tissue infections. The Company mainly conducts its businesses in the domestic market.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board ZhenfuLi 59 6/24/2020 6/24/2020
President, Chief Executive Officer, Executive Director HongZhao 58 6/1/2020 4/1/2013
Chief Financial Officer, Vice President, Executive Director, Company Secretary RongrongPan 45 3/28/2024 8/1/2020
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
SciClone Pharmaceuticals, Inc. 950 Tower Lane Foster City CA United States

General Information
Number of Employees: 1,050 (As of 12/31/2023)
Outstanding Shares: 630,826,562 (As of 6/30/2024)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025